Catalyst Biosciences, Inc. (NASDAQ:CBIO) Short Interest Up 114.5% in August

Catalyst Biosciences, Inc. (NASDAQ:CBIOGet Rating) was the recipient of a significant growth in short interest in August. As of August 31st, there was short interest totalling 1,970,000 shares, a growth of 114.5% from the August 15th total of 918,400 shares. Based on an average daily trading volume, of 1,080,000 shares, the short-interest ratio is presently 1.8 days. Currently, 8.6% of the shares of the company are sold short.

Hedge Funds Weigh In On Catalyst Biosciences

A number of large investors have recently added to or reduced their stakes in CBIO. Prudential Financial Inc. acquired a new stake in shares of Catalyst Biosciences in the second quarter valued at about $36,000. Virtu Financial LLC acquired a new stake in shares of Catalyst Biosciences in the second quarter valued at about $96,000. Bank of New York Mellon Corp raised its position in shares of Catalyst Biosciences by 187.9% in the first quarter. Bank of New York Mellon Corp now owns 216,807 shares of the biopharmaceutical company’s stock valued at $143,000 after buying an additional 141,498 shares during the last quarter. Acadian Asset Management LLC acquired a new stake in shares of Catalyst Biosciences in the fourth quarter valued at about $211,000. Finally, Nantahala Capital Management LLC raised its position in shares of Catalyst Biosciences by 13.8% in the second quarter. Nantahala Capital Management LLC now owns 2,755,903 shares of the biopharmaceutical company’s stock valued at $4,906,000 after buying an additional 335,114 shares during the last quarter. 40.63% of the stock is currently owned by institutional investors and hedge funds.

Catalyst Biosciences Stock Performance

NASDAQ:CBIO opened at $1.96 on Thursday. The company has a fifty day moving average of $1.86 and a two-hundred day moving average of $1.22. The stock has a market capitalization of $61.69 million, a PE ratio of -7.54 and a beta of 1.36. Catalyst Biosciences has a fifty-two week low of $0.35 and a fifty-two week high of $5.20.

Catalyst Biosciences (NASDAQ:CBIOGet Rating) last posted its quarterly earnings data on Monday, August 15th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.24) by $0.06. Catalyst Biosciences had a negative net margin of 1,200.77% and a negative return on equity of 126.39%. Research analysts forecast that Catalyst Biosciences will post -0.25 earnings per share for the current year.

Catalyst Biosciences Increases Dividend

The business also recently disclosed a dividend, which will be paid on Tuesday, September 20th. Shareholders of record on Tuesday, September 6th will be given a dividend of $1.43 per share. The ex-dividend date of this dividend is Friday, September 2nd. This is a boost from Catalyst Biosciences’s previous dividend of $0.57.

Catalyst Biosciences Company Profile

(Get Rating)

Catalyst Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on developing protease product candidates in the fields of hemostasis and complement regulation. The company's protease engineering platform creates improved or novel molecules to treat diseases that result from dysregulation of the complement system.

Read More

Receive News & Ratings for Catalyst Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catalyst Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.